Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Icecure Medical Ltd ICCM

Healthcare Medical Care Medical Devices
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical... see more

Recent & Breaking News (NDAQ:ICCM)

IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogenic Pump for its Next-Generation Cryoablation Systems

PR Newswire January 18, 2023

IceCure Medical CEO Issues Letter to Shareholders

PR Newswire January 4, 2023

IceCure Medical Ltd. Announces Closing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

PR Newswire December 23, 2022

IceCure Medical Ltd. Announces Pricing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

PR Newswire December 21, 2022

IceCure Medical Ltd. Announces Proposed Public Offering

PR Newswire December 20, 2022

IceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results

PR Newswire December 19, 2022

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

PR Newswire December 6, 2022

IceCure Medical Reports Financial Results for the Nine Months Ended September 30, 2022 and Provides Update on Recent Operational Highlights

PR Newswire December 5, 2022

IceCure's ProSense Featured in Poster Presentation at Radiological Society of North America's 2022 Annual Meeting

PR Newswire November 30, 2022

TIME CHANGE: IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022

PR Newswire November 29, 2022

IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022

PR Newswire November 28, 2022

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

PR Newswire November 8, 2022

IceCure Launches Global #FreezeCancerNotYourLife Movement During Breast Cancer Awareness Month

PR Newswire October 26, 2022

IceCure Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense® with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

PR Newswire October 19, 2022

IceCure Medical's ProSense® Cryoprobes and Introducers Receive Regulatory Approval in Brazil

PR Newswire October 11, 2022

IceCure Submits Regulatory Filing in Vietnam for Approval of ProSense®

PR Newswire August 29, 2022

IceCure Medical Reports Financial Results for the First Half of 2022 and Recent Operational Highlights

PR Newswire August 15, 2022

IceCure Medical to Report H1 2022 Results and Conduct Conference Call on August 15, 2022

PR Newswire August 9, 2022

IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

PR Newswire July 25, 2022

Former Itamar Medical CEO & President Gilad Glick Joins IceCure Medical as a Strategic Advisor for Global Go-To-Market Operations

PR Newswire July 5, 2022